Telomir Pharmaceuticals (TELO) grants 50,000 stock options to director
Rhea-AI Filing Summary
Telomir Pharmaceuticals, Inc. reported that director Matthew Paul Del Giudice received a grant of 50,000 non-qualified stock options on April 16, 2026. The options have an exercise price of $1.34 per share, equal to the closing price that day, and vested immediately upon issuance. They are exercisable for common stock and expire on April 16, 2036, resulting in Del Giudice holding 50,000 options after the grant, awarded under the company’s 2023 Omnibus Incentive Plan. The transaction was not made under a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Del Giudice Matthew Paul
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Options (right to buy) F1, F2 | 50,000 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Options (right to buy) — 50,000 shares (Direct)
Footnotes (2)
- F1. The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on April 16, 2026.
- F2. The stock options were issued to the Reporting Person on April 16, 2026, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). All of the options vested immediately upon issuance.
Key Figures
Options Granted: 50,000 options
Exercise Price: $1.34 per share
Post-Grant Option Holdings: 50,000 options
+1 more
4 metrics
Options Granted
50,000 options
Non-qualified stock options granted to director on April 16, 2026
Exercise Price
$1.34 per share
Exercise price equal to closing common stock price on April 16, 2026
Post-Grant Option Holdings
50,000 options
Total options held by Matthew Paul Del Giudice after the transaction
Option Expiration Date
2036-04-16
Expiration date of the granted non-qualified stock options
Key Terms
Non-Qualified Stock Options, exercise price, 2023 Omnibus Incentive Plan, Rule 10b5-1
4 terms
Non-Qualified Stock Options financial
"security_title: "Non-Qualified Stock Options (right to buy)""
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
exercise price financial
"The exercise price of the stock options issued to the Reporting Person"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
2023 Omnibus Incentive Plan financial
"pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan"
Rule 10b5-1 regulatory
"Rule 10b5-1 trading plans affect how insider transactions are pre-arranged"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Telomir Pharmaceuticals (TELO) disclose for Matthew Paul Del Giudice?
Telomir Pharmaceuticals disclosed that director Matthew Paul Del Giudice received a grant of 50,000 non-qualified stock options. The options were awarded on April 16, 2026, vesting immediately and giving him the right to purchase common stock at a fixed exercise price.
What is the exercise price of the Telomir (TELO) stock options granted to Matthew Paul Del Giudice?
The granted options carry an exercise price of $1.34 per share. This price equals the closing price of Telomir’s common stock on April 16, 2026, aligning the option strike with the market price on the grant date.
How many Telomir (TELO) options does Matthew Paul Del Giudice hold after this grant?
After the grant, Matthew Paul Del Giudice holds 50,000 stock options. These options were all acquired in this single award and represent his reported post-transaction derivative holdings in Telomir common stock options.
When do Matthew Paul Del Giudice’s Telomir (TELO) stock options expire?
The options granted to Matthew Paul Del Giudice expire on April 16, 2036. This gives him a ten-year window from the April 16, 2026 grant date to exercise the options and purchase Telomir common shares.
Did the Telomir (TELO) option grant to Matthew Paul Del Giudice vest immediately?
Yes, all of the granted options vested immediately upon issuance. According to the disclosure, the entire 50,000-option award was fully vested on April 16, 2026, with no additional time-based vesting conditions remaining.
Was the Telomir (TELO) option grant to Matthew Paul Del Giudice made under a Rule 10b5-1 trading plan?
No, the grant was not made under a Rule 10b5-1 trading plan. The Rule 10b5-1 checkbox associated with the reported transaction is marked as false, indicating it is not pursuant to an established trading plan.
Under which plan were the Telomir (TELO) options granted to Matthew Paul Del Giudice?
The options were granted under Telomir’s 2023 Omnibus Incentive Plan, as amended and restated. This plan governs the terms of the award, including the immediate vesting and the right to acquire common stock upon exercise.